



ATTORNEY'S DOCKET NO. R0547/7007 (ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James K. Liao, et al.  
Serial No. 09/273,445  
Filed: March 19, 1999  
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE  
SYNTHASE BY HMG-COA REDUCTASE INHIBITORS  
Examiner: Webman E. J.  
Art Unit: 1617

---

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the 13th day of December, 2000.

Konstantinos Andrikopoulos  
Konstantinos Andrikopoulos

---

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- Preliminary Amendment  
 Return Postcard


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No fee is required. If any fee is determined to be due by the Examiner, the Examiner is authorized to charge the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,

Edward R. Gates, Reg. No.: 31,616  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617)720-3500

Attorney's Docket No.: R0547/7007  
Date: December 13, 2000  
xNDD



ATTORNEY'S DOCKET NO. R0547/7007 (ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James K. Liao, et al.  
Serial No. 09/273,445  
Filed: March 19, 1999  
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE  
SYNTHASE BY HMG-COA REDUCTASE INHIBITORS  
Examiner: Webman E. J.  
Art Unit: 1617

*DR 10B*

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the 13th day of December, 2000.

Konstantinos Andrikopoulos  
Konstantinos Andrikopoulos

---

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Sir:

**PRELIMINARY AMENDMENT**

Please amend the above-identified application as follows:

In the claims:

Please cancel claims 177-178, 183-184, 188-189, 197-198, 201-202, 207-212, and 213-214.

*2* Please amend claims 179, 185, 190, 196, 199, 203, and 215, as follows: *2*

*31* 179. (Amended) The method of claim [177] 167-174, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.

*32* 185. (Amended) The method of claim [183] 181, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.

*33* 190. (Amended) The method of claim [188] 187, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.